MCK · McKesson

The thesis

McKesson's shares are more likely than not to beat the S&P 500 over the next three months because its earnings keep running ahead of its own guidance. The 4 November 2026 report lifted fiscal 2027 adjusted earnings per share (EPS) guidance to $45.60–$46.40, the second raise this fiscal year. The fiscal third-quarter report, expected in early February 2027, settles whether profit growth holds as oncology revenue growth slows and second-half investment rises.

The rating is Medium because the business evidence is strong but the price has already moved. The shares closed at $1,079.79 on 11 November 2026, up 26.2% over three months in adjusted daily closes and well above the 50-day average of $948.42. JPMorgan raised its target to $1,255 from $1,042 on 10 November 2026 (Benzinga), the latest in a run of post-report increases.

The market already prices in the raised guidance: the shares sit 3.7% below the $1,121.50 intraday 52-week high of 5 November 2026, and most post-report targets cluster between $1,200 and $1,260 (fiscal.ai, 6 November 2026). Before February, the dated events are deal milestones for Option Care Health: an antitrust waiting period expected to end on 3 December 2026 and the Option Care stockholder vote on 15 December 2026.

Bullish and bearish views on McKesson Corporation

The bull case on McKesson Corporation (MCK), in brief: guidance rose across the business. The bear case: Oncology revenue growth is slowing.

Bull case

• Guidance rose across the business. On 4 November 2026 McKesson lifted fiscal 2027 revenue growth guidance to 6%–10% from 5%–9% and adjusted operating profit growth guidance to 12%–16% from 9%–13% (Zacks via Yahoo Finance). Adjusted EPS guidance moved to $45.60–$46.40 from $44.20–$45.00, against a $44.71 consensus at the time of the report (Benzinga, 4 November 2026).
• Core distribution is widening margins. North American Pharmaceutical revenue rose 6% to $91.36 billion in fiscal Q2 while adjusted operating profit rose 22% to $1.04 billion. GLP-1 weight-loss and diabetes drug revenue reached about $16 billion, up 26% (4 November 2026 earnings call).
• Oncology profit is stronger than the headline. Oncology & Multispecialty adjusted operating profit rose 8% to $427 million, or 23% excluding $51 million of prior-year gains (Zacks, 4 November 2026). Management said on the call that same-store patient visits reached their highest level in recent quarters.
• A closed deal extends the specialty push. The roughly $2.25 billion Precision Medicine Group purchase closed on 2 November 2026. Management expects $0.10–$0.20 of fiscal 2027 adjusted EPS, rising to $1.60–$1.80 by year three (4 November 2026 earnings call).
• The largest customer is locked in. The CVS Health distribution agreement now runs through June 2032, starting 1 October 2026 (4 November 2026 earnings call).
• Cash returns continue. McKesson repurchased $3.4 billion of shares in the first half of fiscal 2027 and targets about $5 billion for the year, with free cash flow guidance of $4.5–$4.9 billion (4 November 2026 earnings call).
• Analyst targets keep moving up. JPMorgan raised its target to $1,255 from $1,042 with an Overweight rating on 10 November 2026 (Benzinga). UBS went to $1,250 from $1,200 on 6 November 2026, and TD Cowen, Evercore ISI and Leerink Partners each moved to $1,200 on 5 November 2026 (Benzinga).
• Peers confirm the demand. Cardinal Health raised fiscal 2027 non-GAAP EPS guidance to $12.80–$13.00 from $12.40–$12.60, and Cencora guided fiscal 2027 adjusted EPS to $19.40–$19.75 (Form 8-K exhibits, early November 2026).

Bear case

• Oncology revenue growth is slowing. Oncology & Multispecialty revenue growth fell to 24% in fiscal Q2 from 33% in fiscal Q1, and the full-year outlook is 20%–24% (4 November 2026 earnings call). Management also warned of quarterly variability in segment profit.
• Second-half spending meets tougher comparisons. Management guided to higher investment in the second half of fiscal 2027 (4 November 2026 earnings call). The 22% fiscal Q2 profit growth in North American Pharmaceutical is the bar the next two reports are measured against.
• Medical-Surgical profit is shrinking. Medical-Surgical Solutions adjusted operating profit fell 10% to $225 million in fiscal Q2, and its fiscal 2027 outlook is down 4% to flat (Zacks, 4 November 2026). The unit is slated for separation as Wellverse.
• Not every analyst sees upside. RBC Capital kept a Sector Perform rating with a $965 target on 5 November 2026 (Benzinga), below the $1,079.79 close of 11 November 2026.
• One executive keeps selling into strength. Chief Information Officer Francisco Fraga sold 800 shares at $995.80 on 15 October 2026, 600 at $1,050.00 on 4 November 2026 and 650 at $1,102.96 on 5 November 2026, all under a Rule 10b5-1 trading plan (SEC Form 4 filings). The amounts are small against McKesson's size.
• The Option Care deal adds commitments. McKesson and Clayton, Dubilier & Rice (CD&R) are buying Option Care Health at $32.05 a share, with McKesson investing about $1.4 billion for a 49% stake (Fierce Healthcare). Option Care's definitive proxy of 9 November 2026 names McKesson a guarantor of a $291.9 million termination fee, and fiscal 2027 guidance excludes the deal.

Price setup

The shares closed at $1,079.79 on 11 November 2026, 3.7% below the $1,121.50 intraday 52-week high reached on 5 November 2026. Since the report they have closed between $1,059.37 (9 November 2026) and $1,082.59 (10 November 2026), holding nearly all of the post-report gain.

As of 11 November 2026 the 50-day average stands at $948.42 and the 200-day average at $870.44, both well under the last close. The 3-month change is 26.2%, and the 52-week closing low was $725.17 on 11 May 2026.

The kill line sits just under where the shares traded before the 4 November 2026 report, so a close there would erase the whole reaction to the guidance raise. A close above $1,121.50 would set a new 52-week high. Between those two points, no company report is scheduled until February, so the shares lean on the deal milestones in December and on peers.

Catalysts ahead

• 1 December 2026: Record date for the $0.94 quarterly dividend payable 4 January 2027. A routine dated event that confirms the dividend continues; it settles nothing in the earnings case.
• ~3 December 2026 (est.): Expected end of the Hart-Scott-Rodino antitrust waiting period for the Option Care Health deal. Expiry without a second request from the FTC or DOJ would clear the main antitrust hurdle; a second request would delay the deal and keep McKesson's roughly $1.4 billion commitment open longer.
• 15 December 2026: Option Care Health special stockholder meeting to vote on the merger. Approval by a majority of outstanding Option Care shares is required; a failed vote would end McKesson's planned 49% stake in home infusion.
• ~3 February 2027 (est.): Fiscal Q3 2027 report. Tests North American Pharmaceutical profit growth against second-half investment and Oncology & Multispecialty against its 20%–24% revenue outlook; a further guidance raise would extend the case.
• ~30 September 2027 (est.): Planned Wellverse initial public offering, expected in the second half of calendar 2027. Settles whether the Medical-Surgical separation happens on schedule, removing a unit whose profit is declining.

What would change the view

A daily close below $990, under the pre-report price of late October 2026, which would erase the whole reaction to the 4 November 2026 guidance raise; or a later report that cuts fiscal 2027 adjusted EPS guidance of $45.60–$46.40.

The risks this note tracks, each with what would confirm it:

• Oncology & Multispecialty revenue growth keeps slowing from 33% in fiscal Q1 and 24% in fiscal Q2. Confirmed by: segment revenue growth below the 20% low end of the full-year outlook, or a lowered segment outlook, in the fiscal Q3 or Q4 report.
• Second-half investment and tougher comparisons compress North American Pharmaceutical profit growth from the 22% of fiscal Q2. Confirmed by: segment profit growth below 14% in a report, or a lowered segment outlook.
• Expectations run ahead of the business after the cluster of target raises from 5 November to 10 November 2026. Confirmed by: the shares giving back the post-report gain with no change in guidance, or target cuts from firms that raised in November 2026.
• The August 2026 data breach brings regulatory, legal or customer costs in the oncology and medical-surgical units. Confirmed by: a company disclosure confirming a large patient-record count, a regulator inquiry, or a breach-related charge in results.
• The Option Care Health deal faces regulatory or stockholder obstacles. Confirmed by: a second request from the FTC or DOJ around 3 December 2026, a failed stockholder vote on 15 December 2026, or a widening gap between Option Care's share price and the $32.05 offer.
• The Wellverse separation slips or happens on worse terms. Confirmed by: a company statement delaying the offering beyond the second half of 2027, or further declines in Medical-Surgical profit.

What it trades with

McKesson trades with the other two large US drug distributors, Cardinal Health and Cencora, which raised or set higher fiscal 2027 guidance in the same weeks of October and November 2026. A sector-wide shock such as a drug-pricing policy change or a slowdown in GLP-1 volumes would hit all three at once.

The business earns distribution margins on drug volume, whoever makes the drug, so it tracks prescription volumes and specialty-drug demand more than medical-cost trends. Its link to health insurers such as Humana is loose. McKesson's case rests on its own reports, and a further guidance raise in February would support it regardless of how the wider health-services group trades.